Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives.

Overwater IE, Rietman AB, van Eeghen AM, de Wit MCY.

Ther Clin Risk Manag. 2019 Jul 26;15:951-955. doi: 10.2147/TCRM.S145630. eCollection 2019. Review.

PMID:
31440057
2.

A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex.

Overwater IE, Rietman AB, Mous SE, Bindels-de Heus K, Rizopoulos D, Ten Hoopen LW, van der Vaart T, Jansen FE, Elgersma Y, Moll HA, de Wit MY; ENCORE Expertise Centre for Neurodevelopmental Disorders.

Neurology. 2019 Jul 9;93(2):e200-e209. doi: 10.1212/WNL.0000000000007749. Epub 2019 Jun 19.

PMID:
31217257
3.

Cortical dysplasia and autistic trait severity in children with Tuberous Sclerosis Complex: a clinical epidemiological study.

Mous SE, Overwater IE, Vidal Gato R, Duvekot J, Ten Hoopen LW, Lequin MH, de Wit MY, Dieleman GC.

Eur Child Adolesc Psychiatry. 2018 Jun;27(6):753-765. doi: 10.1007/s00787-017-1066-z. Epub 2017 Oct 23.

4.

Author response: Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial.

de Wit MY, Overwater IE.

Neurology. 2017 Mar 7;88(10):1008. doi: 10.1212/WNL.0000000000003704. No abstract available.

PMID:
28265043
5.

Interdependence of clinical factors predicting cognition in children with tuberous sclerosis complex.

Overwater IE, Verhaar BJ, Lingsma HF, Bindels-de Heus GC, van den Ouweland AM, Nellist M, Ten Hoopen LW, Elgersma Y, Moll HA, de Wit MC.

J Neurol. 2017 Jan;264(1):161-167. doi: 10.1007/s00415-016-8335-5. Epub 2016 Nov 22.

6.

Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial.

Overwater IE, Rietman AB, Bindels-de Heus K, Looman CW, Rizopoulos D, Sibindi TM, Cherian PJ, Jansen FE, Moll HA, Elgersma Y, de Wit MC.

Neurology. 2016 Sep 6;87(10):1011-8. doi: 10.1212/WNL.0000000000003077. Epub 2016 Aug 10.

PMID:
27511181
7.

Genotype and brain pathology phenotype in children with tuberous sclerosis complex.

Overwater IE, Swenker R, van der Ende EL, Hanemaayer KB, Hoogeveen-Westerveld M, van Eeghen AM, Lequin MH, van den Ouweland AM, Moll HA, Nellist M, de Wit MY.

Eur J Hum Genet. 2016 Dec;24(12):1688-1695. doi: 10.1038/ejhg.2016.85. Epub 2016 Jul 13.

8.

Treatment of Cognitive Deficits in Genetic Disorders: A Systematic Review of Clinical Trials of Diet and Drug Treatments.

van der Vaart T, Overwater IE, Oostenbrink R, Moll HA, Elgersma Y.

JAMA Neurol. 2015 Sep;72(9):1052-60. doi: 10.1001/jamaneurol.2015.0443. Review.

PMID:
26168015
9.

Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs.

Overwater IE, Bindels-de Heus K, Rietman AB, Ten Hoopen LW, Vergouwe Y, Moll HA, de Wit MC.

Epilepsia. 2015 Aug;56(8):1239-45. doi: 10.1111/epi.13050. Epub 2015 Jun 4.

10.

Treatment of intractable epilepsy in tuberous sclerosis complex with everolimus is not yet evidence-based.

Overwater IE, Rietman AB, Elgersma Y, de Wit MC.

Ann Neurol. 2014 Jan;75(1):163-4. doi: 10.1002/ana.24047. Epub 2014 Jan 2. No abstract available.

PMID:
24243580
11.

TORC1-dependent epilepsy caused by acute biallelic Tsc1 deletion in adult mice.

Abs E, Goorden SM, Schreiber J, Overwater IE, Hoogeveen-Westerveld M, Bruinsma CF, Aganović E, Borgesius NZ, Nellist M, Elgersma Y.

Ann Neurol. 2013 Oct;74(4):569-79. doi: 10.1002/ana.23943. Epub 2013 Sep 10.

PMID:
23720219

Supplemental Content

Loading ...
Support Center